A comprehensive analysis of clinical and preclinical data reveals that GLP-1 receptor agonists, previously suspected of increasing cancer risk, are generally safe and may even reduce the incidence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback